Cocrystal Pharma (NASDAQ:COCP) Director Acquires $47,500.00 in Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost bought 50,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were acquired at an average price of $0.95 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director owned 1,888,551 shares in the company, valued at $1,794,123.45. This represents a 2.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 31st, Phillip Md Et Al Frost purchased 50,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.95 per share, with a total value of $47,500.00.
• On Tuesday, December 30th, Phillip Md Et Al Frost acquired 20,000 shares of Cocrystal Pharma stock. The shares were bought at an average cost of $0.97 per share, for a total transaction of $19,400.00.
• On Friday, December 26th, Phillip Md Et Al Frost acquired 40,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, December 24th, Phillip Md Et Al Frost bought 25,000 shares of Cocrystal Pharma stock. The stock was bought at an average cost of $0.97 per share, with a total value of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The stock was bought at an average cost of $0.99 per share, for a total transaction of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.94 per share, for a total transaction of $18,800.00.

Cocrystal Pharma Price Performance

Cocrystal Pharma stock opened at $0.95 on Thursday. Cocrystal Pharma, Inc. has a 52-week low of $0.86 and a 52-week high of $2.67. The stock has a fifty day moving average price of $1.02 and a two-hundred day moving average price of $1.20. The firm has a market capitalization of $13.16 million, a P/E ratio of -1.02 and a beta of 1.20.

Cocrystal Pharma (NASDAQ:COCP) last announced its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. On average, equities research analysts predict that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. T3 Companies LLC bought a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma at the end of the most recent quarter. 6.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.